<DOC>
	<DOCNO>NCT01339962</DOCNO>
	<brief_summary>Non-interventional study . Data obtain patient chart review . Retrospective analysis progression free survival , time treatment failure overall survival national cohort patient metastatic renal cell carcinoma treat Denmark 2006-2010 Safety , prognostic factor , predictive factor co-morbidity assess Charlson Comorbidity Index . The following drug evaluate : Sunitinib , Sorafenib , Temsirolimus , Everolimus , Aldesleukin , Interferon-alfa-2b .</brief_summary>
	<brief_title>Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010 . DARENCA Study 2 .</brief_title>
	<detailed_description>No sampling . All eligible patient include .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Metastatic renal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Metastatic renal cell carcinoma</keyword>
</DOC>